Susana de la Luna

Susana de la Luna

Centre de Regulació Genòmica

Life & Medical Sciences

I obtained a BsC in Biology in 1985 at Universidad Autónoma de Madrid. For my PhD studies, I joined Juan Ortín's lab at the CBMSO and worked on the biology of influenza virus, characterizing molecularly and functionally the viral polymerase. After getting the PhD in 1989 at UAM, I stayed in Ortín's lab at CNB until 1994 when I moved to London to the lab of Nick La Thangue at the National Institute for Medical Research. There, I worked on the G1/S transition in the mammalian cell cycle focusing in the transcription factor E2F, with fellowships from the HFSO (at NIMR) and EU-Marie Curie (at Glasgow University) Programs. In 1998, I returned to Spain with a reintegration contract to join the HSA21/Down syndrome Research group led by Xavier Estivill (IRO, Barcelona). In 2002, I joined ICREA and established my own research group working on the functional characterization of the family of kinases DYRK and their relationship with disease at the Centre for Genomic Regulation-CRG.

Research interests

Protein kinases are central to all cellular processes in eukaryotes, and often linked to disease when they are altered. My group works on a family of protein kinases known as DYRK (dual-specificity tyrosine-regulated kinases), whose members -DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4- participate in the regulation of processes critical for cell viability and homeostasis. In general, alterations in DYRKs (expression or mutation) are linked to different cancer types. In addition, mutations in several DYRK genes are associated to developmental disorders, as in the case of the DYRK1A haploinsufficiency syndrome or the DYRK1B-associated metabolic syndrome. My group aims to dissect how DYRK activities are linked to human pathology. We are particularly interested on the DYRK-associated activities that impact on the regulation of expression programs either directly on chromatin or indirectly through modulation of signaling pathways.

Selected publications

- Lara-Chica M, Correa-Sáez A, Jiménez-Izquierdo R, Garrido-Rodríguez M, Ponce FJ, Moreno R, Morrison K, Di Vona C, Arató K, Jiménez-Jiménez C, Morrugares R, Schmitz ML, de la Luna S, de la Vega L & Calzado MA, 2022, 'A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival', Cell Death and Differerentiation, vol. 29, no. 1, pp 105–117.

- Boni J, Rubio-Perez C, López-Bigas N, Fillat C  & de la Luna S 2020, ' The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities' In 'Non-canonical kinases and substrates in cancer progression', pp 21-46, Vega FM (ed.),  MDPI, Basel. ISBN 978-3-0365-3055-0.

- de Llobet Cucalon LI, Di Vona C, Morselli M, Vezzoli M, Montanini B, Teichmann M, de la Luna S & Ferrari R, 2022, 'An RNA Polymerase III general transcription factor engages in cell type-specific chromatin looping', International Journal of Molecular Sciences, vol. 23, no. 4, pp 2260-2273.

- Luque J, Mendes I et al. 2022, 'CIBERER: Spanish National Network for Research on Rare Diseases: a highly productive collaborative initiative', Clinical Genetics, vol. 101, no. 5-6, pp 481-493.